Description
P1.17 DNA hydroxymethylation in chronic lymphocytic leukemia: TET and IDH mRNA expression, prognostic significance and influence of microenvironment
- You cannot add another "Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma" to your cart. View cart
Article: P1.17 DNA hydroxymethylation in chronic lymphocytic leukemia: TET and IDH mRNA expression, prognostic significance and influence of microenvironment
€2.42
Related products
-
Article: Highlights in squamous cell carcinoma of the head and neck
€2.42 Add to cart -
Article: Highlights in melanoma
€2.42 Add to cart -
Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma
€2.42 Add to cart -
Article: Highlights in breast cancer
€2.42 Add to cart
Reviews
There are no reviews yet.